Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies
Proceedings of the National Academy of Sciences · 31.03.2026 · 123 (13)
DOI: 10.1073/pnas.2522090123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 25.03.2026. Verfasst von Cameron T Flower und 1 weiteren Autor:innen. Beteiligte Einrichtung: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Signal Transduction, Proteome, Phosphoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
Tyrosine kinases (TKs) are frequently mutated or overexpressed in cancer, and TK inhibitors (TKIs) are an important therapeutic modality against TK-driven cancers, but many patients show an underwhelming response to TKIs prescribed on the basis of tumor genotype. To find cell-intrinsic TK signaling patterns which might be predictive of poor response to TKI therapies, we used high-sensitivity multiplexed mass spectrometry to quantify endogenous levels of 1,222 phosphotyrosine (pY) sites across the proteomes of TK-driven human cancer cell lines with variable response to genotype-matched TKIs. In direct comparisons between TKI-tolerant and TKI-sensitive lines with a common driver TK, we found that TKI treatment was equally effective at blocking driver TK signaling, and higher basal activity of the driver TK did not always predict higher sensitivity to TKI. All tolerant lines showed a dampened proteome-wide pY response to TKI exposure compared to sensitive lines, suggesting that tumor cells with more robust TK signaling are less vulnerable to driver TK blockade. We found that each tolerant line depends on a unique set of compensatory TKs and signaling axes but are unified by hyperactivity of at least one of the SRC family kinases (SFKs) or the related ABL1/2 kinases, both at rest and under TKI treatment, despite the absence of SFK or ABL genetic mutations. In time- and dose-resolved drug combination experiments, SFK/ABL inhibitors were potently synergistic with all TKIs tested, demonstrating that elevated SFK/ABL signaling is a conserved bottleneck for maximal TKI efficacy which could be exploited therapeutically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
- Program in Computational and Systems Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
ORCID-Profile: Cameron T Flower, Forest M White
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Flower, C. T., & White, F. M. (2026). Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies. Proceedings of the National Academy of Sciences, 123(13). https://doi.org/10.1073/pnas.2522090123
Vancouver
Flower CT, White FM. Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies. Proceedings of the National Academy of Sciences. 2026;123(13). doi:10.1073/pnas.2522090123
BibTeX
@article{Flower2026,
author = {Flower, Cameron T and White, Forest M},
title = {Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {13},
doi = {10.1073/pnas.2522090123}
}
EUVIMED